Summary Information of Listed U.S. Post Marketing Commitments
To review summary information of Pfizer U.S. post marketing medicines, select from the following:
- Total Listed U.S. Post Marketing Commitments (all statuses, including Fulfilled, Released, and Terminated)
- Total Active U.S. Post Marketing Commitments (includes Pending, On-going, Delayed, and Submitted)
- U.S. Post Marketing Commitments by Status
- U.S. Post Marketing Commitments by Type
Total Listed U.S. Post Marketing Commitments
| Pfizer post marketing commitments as of | 04/08/2013 |
|---|---|
|
Listed PMCs (all statuses, including Fulfilled, Released, and Terminated) | 218 |
Total Active U.S. Post Marketing Commitments
| Pfizer post marketing commitments as of | 04/08/2013 |
|---|---|
| Active PMCs (Pending, On-going, Delayed, and Submitted) | 92 |
U.S. Post Marketing Commitments by Status
| Pfizer post marketing commitments as of | 04/08/2013 |
|---|---|
| Pending | 12 |
| On-going | 47 |
| Delayed | 15 |
| Terminated | 1 |
| Submitted | 18 |
| Fulfilled | 107 |
| Released | 19 |
To review individual commitments of specific status, search Medicine-specific U.S. Post Marketing Commitments.
U.S. Post Marketing Commitments by Type
| Pfizer post marketing commitments as of | 04/08/2013 |
|---|---|
| Clinical trial | 105 |
| Pre-clinical | 17 |
| Safety | 26 |
| Pediatric | 38 |
| Special population | 6 |
| New dosage form/strength | 0 |
| Other | 26 |
To review individual commitments of specific type, search Medicine-specific U.S. Post Marketing Commitments.
About the Information Posted on This Web Site:
This Web site contains information about Pfizer’s post marketing commitments for pharmaceutical products in the US and for medicinal products approved via the CAP in the EU. The post marketing commitments listed here include pre-clinical, clinical and epidemiological studies or testing and for the EU other activities agreed to by Pfizer (including its group companies/subsidiaries) and the FDA or European Medicines Agency, and are used to gather additional information about the safety, efficacy, or use of approved Pfizer medicines, or help ensure their safe use. This Web site provides the current status of Pfizer post marketing commitments listed on the FDA Web site. It includes post marketing commitments established for Pfizer medicines in the US since August 1, 2000 and for EU medicinal products approved via the CAP. New post marketing commitments will be added to this Web site as they are established.
This Web site does not contain technical chemistry, manufacturing and control (CMC) commitments, or commitments for medicines for which a Pfizer group company is not the license holder. Information about Pfizer's post marketing commitments is believed to be correct at the time that the information is posted, and is subject to change as progress is made in fulfilling the commitments.
This Web site is updated monthly. The status of post marketing commitments shown on the FDA Web site may differ from information displayed on this site, due to differences in the timing of updates made to the FDA Web site. The number of commitments on the two sites may also differ, due to the frequency of such updates and/or due to multiple reporting of single commitments on the FDA Web site.